Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
Bladder cancer
Cystoscopy
Follow-up
Surveillance
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
received:
13
09
2023
accepted:
09
10
2023
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
aheadofprint
Résumé
There is significant lack on evidence regarding the effect of non-adherence to a recommended protocol in follow-up of high-risk non-muscle-invasive bladder cancer (NMIBC), or the impact of delaying detection of recurrent lesion. Here, we aimed to investigate the optimal frequency of follow-up cystoscopy of high-risk NMIBC with respect to oncological safety in the Japanese real-world clinical practice. This retrospective single-center study included 206 patients with primary high-risk NMIBC. The intensity (%) of follow-up cystoscopy was calculated based on actual visits for cystoscopy and guideline-recommended frequency in the first 24-month follow-up period. Inverse probability of treatment weighting analyses was used to reduce the risk of bias between groups. We performed a restricted cubic spline analysis with knots at intensity of follow-up cystoscopy ≤ 100% group to examine the possible association of progression risk with the intensity of follow-up as a continuous exposure. The median intensity was 87.5% (interquartile range, 75-100). Adjusted multivariate analysis for MIBC-free and progression-free survival demonstrated no significant difference between adjusted ≤ 75% and > 75% intensity groups. A restricted cubic spline analysis suggested no significant effect of the intensity of follow-up on progression risk, and hazard ratios of patients of < 100% intensity were equivalent to those of patients of 100% intensity. Our finding suggested decreased intensity of follow-up cystoscopy did not affect oncological outcomes in patients with high-risk NMIBC. Further prospective trials directly aimed at investigating optimized follow-up schedules for NMIBC are mandatory before substantial changes to existing clinical guidelines.
Identifiants
pubmed: 37910382
doi: 10.1007/s11255-023-03851-3
pii: 10.1007/s11255-023-03851-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H (2020) Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: revision working position paper. Int J Urol 27:362–368. https://doi.org/10.1111/iju.14210
doi: 10.1111/iju.14210
pubmed: 32172529
EAU Guidelines (2023) Edn Presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6
Chang SS, Boorjian SA, Chou R, Clark PE, Siamak D, Konety BR et al (2016) Non-muscle invasive bladder cancer: American urological association/SUO guideline. https://www.auanet.org/education/guidelines/non-muscle-invasive-bladder-cancer.cfm
Schroeck FR, Smith N, Shelton JB (2018) Implementing risk-aligned bladder cancer surveillance care. Urol Oncol 36:257–264. https://doi.org/10.1016/j.urolonc.2017.12.016
doi: 10.1016/j.urolonc.2017.12.016
pubmed: 29395957
pmcid: 5936659
Blick CG, Nazir SA, Mallett S, Turney BW, Onwu NN, Roberts IS, Crew JP, Cowan NC (2012) Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int 110:84–94. https://doi.org/10.1111/j.1464-410X.2011.10664.x
doi: 10.1111/j.1464-410X.2011.10664.x
pubmed: 22122739
Dreyer T, Ernst A, Jensen JB (2022) Optimal intervals for follow-up cystoscopy in non-muscle invasive bladder cancer: a systematic review regarding oncological safety. Scand J Urol 56:39–46. https://doi.org/10.1080/21681805.2021.2014562
doi: 10.1080/21681805.2021.2014562
pubmed: 34913840
Miyamoto T, Miyake M, Nakahama T, Nishimura N, Onishi K, Iida K, Yonemori M, Enokida H, Nakagawa M, Matsumoto H, Matsuyama H, Matsushita Y, Miyake H, Fujii T, Shimada K, Baba S, Kinjyo M, Shimokama T, Okumura K, Fujimoto K, Collaboration N-O group, (2023) Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: a multi-institutional collaborative study. Int J Urol 30:473–481. https://doi.org/10.1111/iju.15162
doi: 10.1111/iju.15162
pubmed: 36788781
Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, Herr H, Lechevallier E, Ribal MJ (2012) Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol 62:290–302. https://doi.org/10.1016/j.eururo.2012.05.008
doi: 10.1016/j.eururo.2012.05.008
pubmed: 22609313
Culpan M, Keser F, Acar HC, Otunctemur A, Kucuk EV, Erdem S, Ozer M, Sen UT, Degirmenci E, Ergul R, Atis RG, Yildirim A (2021) Impact of delay in cystoscopic surveillance on recurrence and progression rates in patients with non-muscle-invasive bladder cancer during the COVID-19 pandemic. Int J Clin Pract 75:e14490. https://doi.org/10.1111/ijcp.14490
doi: 10.1111/ijcp.14490
pubmed: 34117682
Abushamma F, Khayyat Z, Soroghle A, Zyoud HS, Jaradat A, Akkawi M, Aburass H, Qaddumi IKK, Odeh R, Salameh H, Albuheissi S, (2021) The impact of non-compliance to a standardized risk-adjusted protocol on recurrence, progression, and mortality in non-muscle invasive bladder cancer. Cancer Manag Res 13:2937–2945. https://doi.org/10.2147/CMAR.S299148
doi: 10.2147/CMAR.S299148
pubmed: 33833577
pmcid: 8020126
Vellinga A, Cormican M, Hanahoe B, Bennett K, Murphy AW (2011) Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol 11:40. https://doi.org/10.1186/1471-2288-11-40
doi: 10.1186/1471-2288-11-40
pubmed: 21470399
pmcid: 3079702
Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R, Matsumoto K, Numakura K, Inokuchi J, Morizane S, Yoneyama T, Matsumura Y, Abe T, Inoue M, Yamada T, Terada N, Hirao S, Uemura M, Matsushita Y, Taoka R, Kobayashi T, Kojima T, Matsui Y, Kitamura H, Nishiyama H; Japanese Urological Oncology Group (2021) Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. BMC Cancer 21:266. https://doi.org/10.1186/s12885-021-07966-7
doi: 10.1186/s12885-021-07966-7
pubmed: 33706705
pmcid: 7948348
Desquilbet L, Mariotti F (2010) Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 29:1037–1057. https://doi.org/10.1002/sim.3841
doi: 10.1002/sim.3841
pubmed: 20087875
Schroeck FR, Lynch KE, Chang JW, MacKenzie TA, Seigne JD, Robertson DJ, Goodney PP, Sirovich B (2018) Extent of risk-aligned surveillance for cancer recurrence among patients with early-stage bladder cancer. JAMA Netw Open 1:e183442. https://doi.org/10.1001/jamanetworkopen.2018.3442
doi: 10.1001/jamanetworkopen.2018.3442
pubmed: 30465041
pmcid: 6241521
Mossanen M, Wang Y, Szymaniak J, Tan WS, Huynh MJ, Preston MA, Trinh QD, Sonpavde G, Kibel AS, Chang SL (2019) Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol 37:2059–2065. https://doi.org/10.1007/s00345-018-2550-x
doi: 10.1007/s00345-018-2550-x
pubmed: 30446799
Jung A, Nielsen ME, Crandell JL, Palmer MH, Smith SK, Bryant AL, Mayer DK (2020) Health-related quality of life among non-muscle-invasive bladder cancer survivors: a population-based study. BJU Int 125:38–48. https://doi.org/10.1111/bju.14888
doi: 10.1111/bju.14888
pubmed: 31381249